Search by subject: Takeda

Search by object: Takeda

Entity aggregation search for entity1: Takeda

Entity aggregation search for entity2: Takeda

SentenceSentimentTitleUrlDate
BRUSSELS Japans Takeda Pharmaceutical Co Ltd will be allowed to keep a drug used to treat bowel disease because changes in the market have removed the need to sell it to allay EU antitrust concerns over last years acquisition of Shire plc PositiveBRUSSELS Japans Takeda Pharmaceutical Co Ltd will be allowed to keep a drug used to treat bowel disease because changes in the market have removed the need to sell it to allay EU antitrust concerns over last years acquisition of Shire plc http://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-eu/takeda-gets-eu-green-light-to-keep-bowel-drug-after-shire-buy-idUSKBN2342BY2020-05-29
The EU competition enforcer said on Thursday it had reversed its decision after an investigation that followed Takedas request to waive its pledge PositiveBRUSSELS Japans Takeda Pharmaceutical Co Ltd will be allowed to keep a drug used to treat bowel disease because changes in the market have removed the need to sell it to allay EU antitrust concerns over last years acquisition of Shire plc http://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-eu/takeda-gets-eu-green-light-to-keep-bowel-drug-after-shire-buy-idUSKBN2342BY2020-05-29
Takeda Pharmaceutical Co Ltd could start a clinical trial as early as July for a potential treatment of COVID19 that is based on antibodies from recovered patients blood company executives said on Wednesday PositiveTakeda Pharmaceutical Co Ltd could start a clinical trial as early as July for a potential treatment of COVID19 that is based on antibodies from recovered patients blood company executives said on Wednesday http://www.reuters.com/news/health/article/us-health-coronavirus-takeda-pharma-trea/takeda-says-coronavirus-treatment-trial-using-recovered-patients-blood-could-start-in-july-idUSKBN22P3HR2020-05-14
The number of patients who could be aided by Takedas treatment initially called TAK888 depends in part on the availability of blood donations Kim said in an interview with Reuters NeutralTakeda Pharmaceutical Co Ltd could start a clinical trial as early as July for a potential treatment of COVID19 that is based on antibodies from recovered patients blood company executives said on Wednesday http://www.reuters.com/news/health/article/us-health-coronavirus-takeda-pharma-trea/takeda-says-coronavirus-treatment-trial-using-recovered-patients-blood-could-start-in-july-idUSKBN22P3HR2020-05-14
The employment situation is expected to worsen further in April so I think its still the start of a said Atsushi Takeda chief economist at Itochu Research Institute NegativeJobless rate rises to 2 http://www.reuters.com/finance/markets/article/japan-economy-unemployment/japans-march-jobless-rate-rises-to-one-year-high-as-coronavirus-hits-economy-idUSL3N2CF1R52020-04-28
While conditions in Japans labour market arent as severe as in the United States unemployment in the country could rise to in the months ahead Takeda said NegativeJobless rate rises to 2 http://www.reuters.com/finance/markets/article/japan-economy-unemployment/japans-march-jobless-rate-rises-to-one-year-high-as-coronavirus-hits-economy-idUSL3N2CF1R52020-04-28
Takeda Chief Executive Christophe Weber had said last year that a sale of the Japanfocused consumer unit known for its Alinamin line of energy drinks was unlikely NegativeTOKYO Japans Takeda Pharmaceutical Co Ltd http://www.reuters.com/places/japan/article/us-takeda-pharma-consumer-divestiture/japans-takeda-sells-670-million-of-europe-otc-assets-to-pare-debt-idUSKCN2260EI2020-04-25
The announcement followed a report by Nikkei Business that Takeda was seeking to sell its Japanbased consumer health unit for around 400 billion yen NeutralTOKYO Japans Takeda Pharmaceutical Co Ltd http://www.reuters.com/places/japan/article/us-takeda-pharma-consumer-divestiture/japans-takeda-sells-670-million-of-europe-otc-assets-to-pare-debt-idUSKCN2260EI2020-04-25
The sale which includes two manufacturing sites in Denmark and Poland would amount to about million subject to customary legal and regulatory closing conditions Takeda said PositiveTOKYO Takeda Pharmaceutical Co http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-japan-takeda-pharma/japanese-drug-firm-takeda-to-sell-some-assets-in-europe-to-orifarm-idUSKCN2260XM2020-04-25
Following its acquisition of Shire Plc in 2019 for billion Takeda has pledged to dispose of billion worth of noncore assets to pare down debt PositiveTOKYO Japans Takeda Pharmaceutical Co Ltd http://www.reuters.com/places/japan/article/us-takeda-pharma-consumer-divestiture/japans-takeda-plans-to-sell-consumer-health-unit-for-around-3-7-billion-nikkei-idUSKCN2260EI2020-04-24
Ethicon and Takeda have mutually decided to terminate the TachoSil transaction agreeing that it was the right decision given the regulators a representative for Johnson Johnson said in a statement NeutralEthicon and Takeda have mutually decided to terminate the TachoSil transaction agreeing that it was the right decision given the regulators a representative for Johnson Johnson said in a statement http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-tachosil-m-a-johnson-johnson/johnson-johnson-abandons-deal-for-takedas-tachosil-surgical-patch-idUSKCN21S1XG2020-04-11
Japans Takeda has a strategic equity stake in Izana PositiveLONDON UKbased biopharma company Izana Bioscience said it was testing its antibody therapy namilumab for the treatment of patients with rapidly worsening COVID19 at the Humanitas Research Hospitals in Bergamo and Milan in Italy http://www.reuters.com/news/health/article/us-health-coronavirus-therapy-izana/uks-izana-bioscience-tests-rheumatoid-arthritis-drug-in-covid-19-patients-idUSKBN21N0Z92020-04-06
Takedas lawyer said he knows about the contract between Takahashi and the bid committee except for the fact that a contract on marketing activities existed PositiveA businessman who received millions of dollars for his work on Tokyos successful campaign to host the 2020 Olympics which was postponed last week due to the coronavirus said he played a key role in securing the support of a former Olympics powerbroker suspected by French prosecutors of taking bribes to help Japans bid http://www.reuters.com/places/africa/article/us-olympics-2020-lobbying-exclusive/exclusive-japan-businessman-paid-8-2-million-by-tokyo-olympics-bid-lobbied-figure-at-center-of-french-corruption-probe-idUSKBN21I0CX2020-03-31
BRUSSELS EU antitrust regulators have opened a full investigation into Johnson Johnsons acquisition of Takeda Pharmaceuticals surgical patch product TachoSil concerned that the deal could lead to reduced choice and higher prices for customers NegativeBRUSSELS EU antitrust regulators have opened a full investigation into Johnson Johnsons acquisition of Takeda Pharmaceuticals surgical patch product TachoSil concerned that the deal could lead to reduced choice and higher prices for customers http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-takeda-pharma-m-a-johnson-johnson-eu/eu-says-johnson-johnsons-deal-for-takeda-patch-may-harm-competition-idUSKBN21C2GY2020-03-26
These efforts include Gilead Sciences Incs experimental antiviral drug remdesivir and a plasmaderived therapy from Japans Takeda Pharmaceutical Co PositiveSINGAPORE Scientists in Singapore say they have developed a way to track genetic changes that speeds testing of vaccines against a coronavirus that has killed more than 16000 people worldwide http://www.reuters.com/news/sciencehttps://www.reuters.com/article/us-health-coronavirus-singapore-vaccine/singapore-scientists-study-genes-to-fast-track-coronavirus-vaccine-idUSKBN21B0P92020-03-24
Companies including Regeneron Pharmaceuticals Inc Eli Lilly and Co and Takeda Pharmaceutical Co have begun to develop coronavirus treatment candidates but human testing of their drugs has not yet started NegativeU.S. researchers following the lead of scientists in other countries have launched studies to see whether widelyavailable lowcost generic drugs can be used to help treat the illness caused by the new coronavirus http://www.reuters.com/news/health/article/us-health-coronavirus-usa-treatments/two-generic-drugs-being-tested-in-u-s-in-race-to-find-coronavirus-treatments-idUSKBN2161QQ2020-03-20
Hypera joined the bidding process for the Takeda products a month ago the two sources added after months of talks with Brazilian rival EMS failed to result in an agreement PositiveSAO PAULO Brazils Hypera Pharma said on Monday that it has signed a contract to buy a portfolio of 18 products from Japans Takeda Pharmaceutical Co for million http://www.reuters.com/places/japan/article/us-takeda-pharma-hypera/brazils-hypera-pharma-to-acquire-drugs-from-japans-takeda-for-825-million-idUSKBN20P2T12020-03-03
SAO PAULO Brazils Hypera Pharma said on Monday that it has signed a contract to buy a portfolio of 18 products from Japans Takeda Pharmaceutical Co for million PositiveSAO PAULO Brazils Hypera Pharma said on Monday that it has signed a contract to buy a portfolio of 18 products from Japans Takeda Pharmaceutical Co for million http://www.reuters.com/places/japan/article/us-takeda-pharma-hypera/brazils-hypera-pharma-to-acquire-drugs-from-japans-takeda-for-825-million-idUSKBN20P2T12020-03-03
I would see him hanging around with his Takeda 28 told Reuters NeutralTOKYO The imposing home where Carlos Ghosn lived for the last seven months and probably launched a daring escape to avoid Japanese prosecutors is nestled in a leafy enclave of Tokyo where most people pay little attention to Westerners or luxury cars http://www.reuters.com/subjects/middle-easthttps://www.reuters.com/article/us-renault-nissan-ghosn-house/surveillance-in-a-leafy-enclave-ghosns-tokyo-life-was-under-strict-monitoring-idUSKBN1Z01M12020-01-02





SentenceSentimentTitleUrlDate
The U.S. and China have agreed on a Phase One Trade deal so its likely tariffs ill be reduced and a worsening of tensions has been Takeda said PositiveTOKYO Japans exports slipped for a 12th straight month in November as declining shipments to the United States and China hit the tradereliant economy raising the risk of a fourthquarter contraction http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-japan-economy-trade/japans-exports-shrink-for-12th-month-as-u-s-china-demand-falls-idUSKBN1YM0222019-12-18
CHICAGO An additional six months of data from a latestage trial of Takeda Pharmaceutical Cos experimental dengue vaccine again showed it failed to protect against one of the four types of the virus in an important patient group researchers said on Saturday NegativeCHICAGO An additional six months of data from a latestage trial of Takeda Pharmaceutical Cos experimental dengue vaccine again showed it failed to protect against one of the four types of the virus in an important patient group researchers said on Saturday http://www.reuters.com/news/health/article/us-takeda-vaccine-dengue/longer-term-data-fail-to-clear-concern-over-takedas-dengue-vaccine-idUSKBN1XX0GP2019-11-24
Takeda plans to file for approval in the second half of 2020 and will collect safety data for at least years Venkayya said PositiveCHICAGO An additional six months of data from a latestage trial of Takeda Pharmaceutical Cos experimental dengue vaccine again showed it failed to protect against one of the four types of the virus in an important patient group researchers said on Saturday http://www.reuters.com/news/health/article/us-takeda-vaccine-dengue/longer-term-data-fail-to-clear-concern-over-takedas-dengue-vaccine-idUSKBN1XX0GP2019-11-24
Takedas vaccine is based on a dengue 2 virus with DNA from the other three added in NegativeCHICAGO An additional six months of data from a latestage trial of Takeda Pharmaceutical Cos experimental dengue vaccine again showed it failed to protect against one of the four types of the virus in an important patient group researchers said on Saturday http://www.reuters.com/news/health/article/us-takeda-vaccine-dengue/longer-term-data-fail-to-clear-concern-over-takedas-dengue-vaccine-idUSKBN1XX0GP2019-11-24
Japans biggest drugmaker Takeda Pharmaceutical Co Ltd said longterm data show better outcomes for its Alunbrig drug in certain lung cancer patients compared to an existing treatment NegativeJapans biggest drugmaker Takeda Pharmaceutical Co Ltd said longterm data show better outcomes for its Alunbrig drug in certain lung cancer patients compared to an existing treatment http://www.reuters.com/places/japan/article/us-takeda-pharma-alunbrig/takeda-says-cancer-drug-alunbrig-shows-longer-benefit-vs-crizotinib-idUSKBN1XX02D2019-11-23
Takeda is focusing on five key oncology gastroenterology neuroscience rare disease and plasmaderived therapies businesses that contribute about of its total revenue NeutralJapans biggest drugmaker Takeda Pharmaceutical Co Ltd said longterm data show better outcomes for its Alunbrig drug in certain lung cancer patients compared to an existing treatment http://www.reuters.com/places/japan/article/us-takeda-pharma-alunbrig/takeda-says-cancer-drug-alunbrig-shows-longer-benefit-vs-crizotinib-idUSKBN1XX02D2019-11-23
Among roughly a quarter of study subjects with no prior dengue exposure who got Takedas vaccine the shot was percent effective at preventing all four types of dengue NegativeCHICAGO Takeda Pharmaceutical Cos experimental dengue vaccine was highly effective at preventing the mosquitoborne disease in a late stage study but it failed to protect against one type of the virus in people with no prior exposure to dengue http://www.reuters.com/places/africa/article/us-takeda-dengue/takedas-dengue-vaccine-effective-overall-in-study-but-with-major-limitation-idUSKBN1XG3192019-11-07
CHICAGO Takeda Pharmaceutical Cos experimental dengue vaccine was highly effective at preventing the mosquitoborne disease in a late stage study but it failed to protect against one type of the virus in people with no prior exposure to dengue NegativeCHICAGO Takeda Pharmaceutical Cos experimental dengue vaccine was highly effective at preventing the mosquitoborne disease in a late stage study but it failed to protect against one type of the virus in people with no prior exposure to dengue http://www.reuters.com/places/africa/article/us-takeda-dengue/takedas-dengue-vaccine-effective-overall-in-study-but-with-major-limitation-idUSKBN1XG3192019-11-07
Takeda said it plans to file for approval in countries with the biggest dengue burden with the first submission expected in the second half of 2020 PositiveCHICAGO Takeda Pharmaceutical Cos experimental dengue vaccine was highly effective at preventing the mosquitoborne disease in a late stage study but it failed to protect against one type of the virus in people with no prior exposure to dengue http://www.reuters.com/places/africa/article/us-takeda-dengue/takedas-dengue-vaccine-effective-overall-in-study-but-with-major-limitation-idUSKBN1XG3192019-11-07
Takeda will release additional data at a medical conference later this month PositiveCHICAGO Takeda Pharmaceutical Cos experimental dengue vaccine was highly effective at preventing the mosquitoborne disease in a late stage study but it failed to protect against one type of the virus in people with no prior exposure to dengue http://www.reuters.com/places/africa/article/us-takeda-dengue/takedas-dengue-vaccine-effective-overall-in-study-but-with-major-limitation-idUSKBN1XG3192019-11-07
Takeda has pledged to dispose of billion worth of noncore assets following the Shire deal which was the biggest ever overseas acquisition by a Japanese company PositiveGermanys Stada http://www.reuters.com/places/japan/article/us-takeda-pharma-divestiture-stada-arzne/stada-buys-takeda-drug-bundle-to-boost-russia-business-idUSKBN1XF0X62019-11-06
Takeda said it will continue to manufacture the drugs for Acino which is backed by Avista Capital and Nordic Capital NeutralTOKYO Japans Takeda Pharmaceutical Co Ltd http://www.reuters.com/places/japan/article/us-takeda-pharma-divestiture/takeda-sells-mideast-africa-drug-portfolio-to-switzerlands-acino-idUSKBN1WU0TZ2019-10-16
Takeda has apologized and resigned from the International Olympic Committee but maintained his innocence NegativeNEW French authorities investigating corruption in international sports believe a Swiss partner of Japanese advertising giant Dentsu Inc played a central and essential deals used to embezzle sponsorship money and have asked Switzerland to raid its office and seize according to a person with knowledge of the probe and documents related to the case reviewed by Reuters http://www.reuters.com/places/africa/article/us-sports-investigation-dentsu-partner-e/exclusive-french-investigators-focus-on-dentsu-partner-in-sports-corruption-probe-idUSKCN1VH2JY2019-08-28
Another blue chip which made big gains was Takeda Pharmaceutical which gained 5 PositiveTOKYO Aug 1 Japans Nikkei share average recouped early losses and inched up on Thursday supported by a weaker yen which helped offset disappointment that the U.S. Federal Reserve is not embarking on a lengthy easing cycle http://www.reuters.com/finance/markets/article/japan-stocks-midday/japan-stocks-inch-up-weak-yen-helps-offset-fed-disappointment-idUSL4N24X0OI2019-08-01
Takeda is also in the process of divesting its Latin American assets which are valued at about billion NegativeJapans Takeda Pharmaceutical Co http://www.reuters.com/places/japan/article/us-takeda-pharma-divestiture/takeda-kicks-off-sale-of-western-european-drugs-sources-idUSKCN1UC24X2019-07-18
Takeda is hoping to fetch around 1 PositiveJapans Takeda Pharmaceutical Co http://www.reuters.com/places/japan/article/us-takeda-pharma-divestiture/takeda-kicks-off-sale-of-western-european-drugs-sources-idUSKCN1UC24X2019-07-18
Takeda is working with JPMorgan to find a new owner and wants to receive indicative bids after the summer the sources said NeutralJapans Takeda Pharmaceutical Co http://www.reuters.com/places/japan/article/us-takeda-pharma-divestiture/takeda-kicks-off-sale-of-western-european-drugs-sources-idUSKCN1UC24X2019-07-18
A latestage study currently testing Xpovio in combination with Takeda Pharmaceutical Co Ltds Velcade and lowdose dexamethasone will serve as a confirmatory trial the company said NeutralKaryopharm Therapeutics Inc on Wednesday set a listprice for its blood cancer treatment Xpovio at per month following accelerated approval from the U.S. Food and Drug Administration http://www.reuters.com/news/health/article/us-karyopharm-fda/karyopharm-therapeutics-prices-blood-cancer-treatment-after-fda-approval-idUSKCN1TY2FI2019-07-04
French prosecutors are investigating Takeda in the matter although he has not formally been charged PositiveTOKYO Surrounded by reporters in March Tsunekazu Takeda tearyeyed and blinking as cameras flashed around him explained his decision to step down as Japans Olympics chief http://www.reuters.com/places/japan/article/us-olympics-2020-takeda-insight/japans-gentleman-equestrian-at-heart-of-olympics-corruption-probe-idUSKCN1TL01F2019-06-21
Hisamitsu Yabe one of the former Shimoren board members said he did not blame Takeda PositiveTOKYO Surrounded by reporters in March Tsunekazu Takeda tearyeyed and blinking as cameras flashed around him explained his decision to step down as Japans Olympics chief http://www.reuters.com/places/japan/article/us-olympics-2020-takeda-insight/japans-gentleman-equestrian-at-heart-of-olympics-corruption-probe-idUSKCN1TL01F2019-06-21
I did not personally have any involvement in the decisionmaking Takeda said at a January news conference NeutralTOKYO Surrounded by reporters in March Tsunekazu Takeda tearyeyed and blinking as cameras flashed around him explained his decision to step down as Japans Olympics chief http://www.reuters.com/places/japan/article/us-olympics-2020-takeda-insight/japans-gentleman-equestrian-at-heart-of-olympics-corruption-probe-idUSKCN1TL01F2019-06-21
TOKYO Surrounded by reporters in March Tsunekazu Takeda tearyeyed and blinking as cameras flashed around him explained his decision to step down as Japans Olympics chief NeutralTOKYO Surrounded by reporters in March Tsunekazu Takeda tearyeyed and blinking as cameras flashed around him explained his decision to step down as Japans Olympics chief http://www.reuters.com/places/japan/article/us-olympics-2020-takeda-insight/japans-gentleman-equestrian-at-heart-of-olympics-corruption-probe-idUSKCN1TL01F2019-06-21
Takeda has kept a low profile in the past year NegativeTOKYO Surrounded by reporters in March Tsunekazu Takeda tearyeyed and blinking as cameras flashed around him explained his decision to step down as Japans Olympics chief http://www.reuters.com/places/japan/article/us-olympics-2020-takeda-insight/japans-gentleman-equestrian-at-heart-of-olympics-corruption-probe-idUSKCN1TL01F2019-06-21
Takeda was wellliked by the JOC staff NeutralTOKYO Surrounded by reporters in March Tsunekazu Takeda tearyeyed and blinking as cameras flashed around him explained his decision to step down as Japans Olympics chief http://www.reuters.com/places/japan/article/us-olympics-2020-takeda-insight/japans-gentleman-equestrian-at-heart-of-olympics-corruption-probe-idUSKCN1TL01F2019-06-21
Takeda who lives in Tokyo declined to respond in specifics to questions Reuters posed in writing NegativeTOKYO Surrounded by reporters in March Tsunekazu Takeda tearyeyed and blinking as cameras flashed around him explained his decision to step down as Japans Olympics chief http://www.reuters.com/places/japan/article/us-olympics-2020-takeda-insight/japans-gentleman-equestrian-at-heart-of-olympics-corruption-probe-idUSKCN1TL01F2019-06-21
Takeda who was deeply involved in Japans equestrian federation lent the venture an air of prestige the former business partners said PositiveTOKYO Surrounded by reporters in March Tsunekazu Takeda tearyeyed and blinking as cameras flashed around him explained his decision to step down as Japans Olympics chief http://www.reuters.com/places/japan/article/us-olympics-2020-takeda-insight/japans-gentleman-equestrian-at-heart-of-olympics-corruption-probe-idUSKCN1TL01F2019-06-21
Takedas resignation which takes effect in June comes three years after allegations first surfaced that Tokyos Olympics bidding committee had paid more than million to win the 2020 Olympics NegativeTOKYO Surrounded by reporters in March Tsunekazu Takeda tearyeyed and blinking as cameras flashed around him explained his decision to step down as Japans Olympics chief http://www.reuters.com/places/japan/article/us-olympics-2020-takeda-insight/japans-gentleman-equestrian-at-heart-of-olympics-corruption-probe-idUSKCN1TL01F2019-06-21
The softspoken Takeda 71 is a household name in Japan NeutralTOKYO Surrounded by reporters in March Tsunekazu Takeda tearyeyed and blinking as cameras flashed around him explained his decision to step down as Japans Olympics chief http://www.reuters.com/places/japan/article/us-olympics-2020-takeda-insight/japans-gentleman-equestrian-at-heart-of-olympics-corruption-probe-idUSKCN1TL01F2019-06-21
Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a latestage study testing its experimental treatment for amyloidosis as it did not meet the first of two main goals NegativeTakeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a latestage study testing its experimental treatment for amyloidosis as it did not meet the first of two main goals http://www.reuters.com/news/health/article/us-takeda-pharma-study/takeda-scraps-late-stage-amyloidosis-study-idUSKCN1T62P52019-06-06
Treatment with Takedas Ninlaro in combination with dexamethasone did not show a significant improvement in patients overall hematologic response compared to standard of care regimens the company said NegativeTakeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a latestage study testing its experimental treatment for amyloidosis as it did not meet the first of two main goals http://www.reuters.com/news/health/article/us-takeda-pharma-study/takeda-scraps-late-stage-amyloidosis-study-idUSKCN1T62P52019-06-06
U.S.listed shares of Takeda were down about at NeutralTakeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a latestage study testing its experimental treatment for amyloidosis as it did not meet the first of two main goals http://www.reuters.com/news/health/article/us-takeda-pharma-study/takeda-scraps-late-stage-amyloidosis-study-idUSKCN1T62P52019-06-06
Latin America represents around of Takedas revenue PositiveSAO PAULO Japans Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May three sources with knowledge of the matter said http://www.reuters.com/places/japan/article/us-takeda-pharma-divestiture-latam/japans-takeda-expects-binding-offers-for-latam-business-by-end-of-may-sources-idUSKCN1SM28G2019-05-17
SAO PAULO Japans Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May three sources with knowledge of the matter said PositiveSAO PAULO Japans Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May three sources with knowledge of the matter said http://www.reuters.com/places/japan/article/us-takeda-pharma-divestiture-latam/japans-takeda-expects-binding-offers-for-latam-business-by-end-of-may-sources-idUSKCN1SM28G2019-05-17
Takeda expects the business to fetch around billion the sources added NeutralSAO PAULO Japans Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May three sources with knowledge of the matter said http://www.reuters.com/places/japan/article/us-takeda-pharma-divestiture-latam/japans-takeda-expects-binding-offers-for-latam-business-by-end-of-may-sources-idUSKCN1SM28G2019-05-17
Novartis is buying dryeye drug Xiidra from Takeda Pharmaceutical Co for up to NegativeNovartis is buying dryeye drug Xiidra from Takeda Pharmaceutical Co for up to http://www.reuters.com/news/health/article/us-takeda-pharma-xiidra-novartis/novartis-buys-dry-eye-drug-from-takeda-for-up-to-5-3-billion-idUSKCN1SE2UW2019-05-10
Swiss drugmaker Novartis dipped on a deal to buy Takeda Pharmaceuticals eye drug assets for Positivea live blog on European stocks type in an Eikon news http://www.reuters.com/finance/markets/article/europe-stocks/european-shares-tumble-amid-trade-tensions-idUSL3N22L27G2019-05-10
We are working to strategically simplify and optimize our portfolio while also rapidly Takeda CEO Christophe Weber said in a statement PositiveNovartis is buying dryeye drug Xiidra from Takeda Pharmaceutical Co for up to http://www.reuters.com/news/health/article/us-takeda-pharma-xiidra-novartis/novartis-buys-dry-eye-drug-from-takeda-for-up-to-5-3-billion-idUSKCN1SE2UW2019-05-10
In Brazil Takeda owns popular over the counter drug brands NegativeSAO Japans Takeda Pharmaceutical Co Ltd has invited Brazilian pharmaceutical companies and financial investors to bid for its business in Latin America three people with knowledge of the matter said http://www.reuters.com/places/brazil/article/us-takeda-pharma-divestiture-brazil/japans-takeda-invites-brazilian-pharmaceutical-firms-to-bid-for-latam-business-sources-idUSKCN1RG1Z72019-04-05
SAO Japans Takeda Pharmaceutical Co Ltd has invited Brazilian pharmaceutical companies and financial investors to bid for its business in Latin America three people with knowledge of the matter said PositiveSAO Japans Takeda Pharmaceutical Co Ltd has invited Brazilian pharmaceutical companies and financial investors to bid for its business in Latin America three people with knowledge of the matter said http://www.reuters.com/places/brazil/article/us-takeda-pharma-divestiture-brazil/japans-takeda-invites-brazilian-pharmaceutical-firms-to-bid-for-latam-business-sources-idUSKCN1RG1Z72019-04-05
Takeda expects to fetch more than billion for the Latin American operations NeutralSAO Japans Takeda Pharmaceutical Co Ltd has invited Brazilian pharmaceutical companies and financial investors to bid for its business in Latin America three people with knowledge of the matter said http://www.reuters.com/places/brazil/article/us-takeda-pharma-divestiture-brazil/japans-takeda-invites-brazilian-pharmaceutical-firms-to-bid-for-latam-business-sources-idUSKCN1RG1Z72019-04-05
Shire owner Takeda did not immediately respond to a request for comment NeutralWASHINGTON An appeals court on Monday upheld a judges decision dismissing a lawsuit filed by the U.S. Federal Trade Commission to fight the practice of brandname drug companies using a government petition system to delay cheaper generic drugs from coming to market http://www.reuters.com/finance/article/us-shire-lawsuit/ftc-loses-shire-appeal-losing-round-in-fight-against-citizen-petition-abuse-idUSKCN1QE2LU2019-02-26
The finding published in the journal Science could have implications for approved and experimental dengue vaccines by Sanofi Takeda Pharmaceutical Merck Co and Brazils Butantan Institute they said PositiveCHICAGO Prior infection with dengue a mosquitoborne disease that infects nearly 400 million people a year could reduce the risk of contracting Zika nearly by half U.S. and Brazilian researchers reported on Thursday http://www.reuters.com/news/health/article/us-health-zika/prior-dengue-infection-may-protect-against-zika-study-idUSKCN1PW2G92019-02-08
A U.S. jury has ordered Takeda Pharmaceutical Cos Baxalta unit to pay Bayer AG NeutralA U.S. jury has ordered Takeda Pharmaceutical Cos Baxalta unit to pay Bayer AG http://www.reuters.com/legal//www.reuters.com/article/us-takeda-bayer-patent/u-s-jury-orders-takeda-to-pay-bayer-155-million-over-hemophilia-drug-idUSKCN1PU27L2019-02-06
Takeda said it was disappointed with the verdict and will consider its legal options NegativeA U.S. jury has ordered Takeda Pharmaceutical Cos Baxalta unit to pay Bayer AG http://www.reuters.com/legal//www.reuters.com/article/us-takeda-bayer-patent/u-s-jury-orders-takeda-to-pay-bayer-155-million-over-hemophilia-drug-idUSKCN1PU27L2019-02-06
CHICAGO Takeda Pharmaceutical Co said on Tuesday that its experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquitoborne disease meeting the main goal of the Japanese drugmakers latestage clinical trial PositiveCHICAGO Takeda Pharmaceutical Co said on Tuesday that its experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquitoborne disease meeting the main goal of the Japanese drugmakers latestage clinical trial http://www.reuters.com/news/health/article/us-takeda-pharma-vaccine/takeda-dengue-vaccine-meets-main-goal-of-trial-detailed-results-to-come-idUSKCN1PN1JS2019-01-30
Dengue experts have questioned whether Takedas vaccine may pose similar risks to Dengvaxia and the results released on Tuesday were not detailed enough to provide answers PositiveCHICAGO A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquitoborne disease that infects nearly 400 million people each year http://www.reuters.com/places/africa/article/us-takeda-vaccine-dengue/undeterred-by-sanofis-stumble-takeda-takes-similar-path-with-dengue-shot-idUSKCN1PO0F72019-01-30
Takeda executives said they had taken steps to ensure their vaccine did not run into the same issues PositiveCHICAGO A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquitoborne disease that infects nearly 400 million people each year http://www.reuters.com/places/africa/article/us-takeda-vaccine-dengue/undeterred-by-sanofis-stumble-takeda-takes-similar-path-with-dengue-shot-idUSKCN1PO0F72019-01-30
Takeda is undeterred NeutralCHICAGO A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquitoborne disease that infects nearly 400 million people each year http://www.reuters.com/places/africa/article/us-takeda-vaccine-dengue/undeterred-by-sanofis-stumble-takeda-takes-similar-path-with-dengue-shot-idUSKCN1PO0F72019-01-30
Takeda officials are banking on a different result hopeful that their approach will help avoid the setbacks that Sanofi experienced PositiveCHICAGO A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquitoborne disease that infects nearly 400 million people each year http://www.reuters.com/places/africa/article/us-takeda-vaccine-dengue/undeterred-by-sanofis-stumble-takeda-takes-similar-path-with-dengue-shot-idUSKCN1PO0F72019-01-30
Takeda said it will release full details of how the vaccine fared at 15 months after the first dose in a peerreviewed journal as quickly as possible PositiveCHICAGO Takeda Pharmaceutical Co said on Tuesday that its experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquitoborne disease meeting the main goal of the Japanese drugmakers latestage clinical trial http://www.reuters.com/news/health/article/us-takeda-pharma-vaccine/takeda-dengue-vaccine-meets-main-goal-of-trial-detailed-results-to-come-idUSKCN1PN1JS2019-01-30
Takeda will first seek approval in each of the eight countries where its clinical trial took Brazil Colombia Panama Dominican Republic Nicaragua Philippines Thailand and Sri Lanka PositiveCHICAGO A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquitoborne disease that infects nearly 400 million people each year http://www.reuters.com/places/africa/article/us-takeda-vaccine-dengue/undeterred-by-sanofis-stumble-takeda-takes-similar-path-with-dengue-shot-idUSKCN1PO0F72019-01-30
The success of TAK003 is crucial to Takedas vaccine ambitions as the Japanbased drugmaker integrates its billion purchase of Shire Plc PositiveCHICAGO A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquitoborne disease that infects nearly 400 million people each year http://www.reuters.com/places/africa/article/us-takeda-vaccine-dengue/undeterred-by-sanofis-stumble-takeda-takes-similar-path-with-dengue-shot-idUSKCN1PO0F72019-01-30
Those two parts will form the basis of Takedas filings seeking regulatory approvals NeutralCHICAGO Takeda Pharmaceutical Co said on Tuesday that its experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquitoborne disease meeting the main goal of the Japanese drugmakers latestage clinical trial http://www.reuters.com/news/health/article/us-takeda-pharma-vaccine/takeda-dengue-vaccine-meets-main-goal-of-trial-detailed-results-to-come-idUSKCN1PN1JS2019-01-30
We will be looking at this very Hombach said of Takedas data NeutralCHICAGO A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquitoborne disease that infects nearly 400 million people each year http://www.reuters.com/places/africa/article/us-takeda-vaccine-dengue/undeterred-by-sanofis-stumble-takeda-takes-similar-path-with-dengue-shot-idUSKCN1PO0F72019-01-30
I am so pleased for Naomi she deserved this said 52yearold local Hitomi Takeda PositiveHAKUBA Japan Japan rejoiced on Saturday as Naomi Osaka clinched her second consecutive Grand Slam title and reached world number one following her 57 64 victory over Petra Kvitova in the final of the Australian Open http://www.reuters.com/places/japan/article/us-tennis-ausopen-osaka-japan/emergence-of-a-new-queen-japan-celebrates-osakas-victory-idUSKCN1PK0DW2019-01-27
Takaya said there had been no specific signals or from the IOC to Tokyo 2020 organizers regarding Takeda NeutralTOKYO The head of Japans Olympic Committee confirmed that he had been questioned by French authorities in December on Tuesday but repeated his denial there was anything improper about Tokyos bid for the 2020 Games and vowed to prove his innocence http://www.reuters.com/places/japan/article/us-olympics-2020-takeda/japans-olympic-committee-head-denies-impropriety-in-2020-bid-procedures-idUSKCN1P90652019-01-16
A judicial source in France on Friday said Takeda a retired equestrian sportsman was indicted last month by the national financial prosecutors office in Paris NegativeTOKYO Japans Olympic Committee head Tsunekazu Takeda said on Friday he has not been indicted by French authorities and that no improper actions such as bribery took place in connection with Tokyos successful 2020 Summer Games bid http://www.reuters.com/places/japan/article/us-olympics-2020-takeda/joc-head-takeda-no-improper-actions-such-as-bribery-in-tokyo-2020-bid-idUSKCN1P51322019-01-12
Asked about the timing a source close to the French investigation into Takeda said there was no link between the two NegativePARIS The president of Japans Olympic Committee Tsunekazu Takeda is under formal investigation in France for suspected corruption related to Japans successful bid for the 2020 Olympic Games a French judicial source said on Friday http://www.reuters.com/places/africa/article/us-olympics-2020/france-investigates-japans-olympics-chief-on-suspicion-of-corruption-idUSKCN1P50TF2019-01-12
BERLIN The International Olympic Committees ethics commission on Friday opened a file on Japan Olympic Committee chief Tsunekazu Takeda after a judicial source in France said he had been indicted by French prosecutors over the successful bid for the 2020 Olympic Games NegativeBERLIN The International Olympic Committees ethics commission on Friday opened a file on Japan Olympic Committee chief Tsunekazu Takeda after a judicial source in France said he had been indicted by French prosecutors over the successful bid for the 2020 Olympic Games http://www.reuters.com/places/japan/article/us-olympics-2020-ioc/ioc-opens-ethics-file-on-takeda-to-meet-friday-idUSKCN1P513E2019-01-12
In Tokyo Takeda said no improper actions such as bribery had taken place in connection with Tokyos bid and that he had not been charged by French authorities NegativePARIS The president of Japans Olympic Committee Tsunekazu Takeda is under formal investigation in France for suspected corruption related to Japans successful bid for the 2020 Olympic Games a French judicial source said on Friday http://www.reuters.com/places/africa/article/us-olympics-2020/france-investigates-japans-olympics-chief-on-suspicion-of-corruption-idUSKCN1P50TF2019-01-12
PARIS The president of Japans Olympic Committee Tsunekazu Takeda is under formal investigation in France for suspected corruption related to Japans successful bid for the 2020 Olympic Games a French judicial source said on Friday NegativePARIS The president of Japans Olympic Committee Tsunekazu Takeda is under formal investigation in France for suspected corruption related to Japans successful bid for the 2020 Olympic Games a French judicial source said on Friday http://www.reuters.com/places/africa/article/us-olympics-2020/france-investigates-japans-olympics-chief-on-suspicion-of-corruption-idUSKCN1P50TF2019-01-12
TOKYO Japans Olympic Committee head Tsunekazu Takeda said on Friday he has not been indicted by French authorities and that no improper actions such as bribery took place in connection with Tokyos successful 2020 Summer Games bid NegativeTOKYO Japans Olympic Committee head Tsunekazu Takeda said on Friday he has not been indicted by French authorities and that no improper actions such as bribery took place in connection with Tokyos successful 2020 Summer Games bid http://www.reuters.com/places/japan/article/us-olympics-2020-takeda/joc-head-takeda-no-improper-actions-such-as-bribery-in-tokyo-2020-bid-idUSKCN1P51322019-01-12
Takeda is also an IOC member since 2012 and heads its marketing commission NeutralBERLIN The International Olympic Committees ethics commission on Friday opened a file on Japan Olympic Committee chief Tsunekazu Takeda after a judicial source in France said he had been indicted by French prosecutors over the successful bid for the 2020 Olympic Games http://www.reuters.com/places/japan/article/us-olympics-2020-ioc/ioc-opens-ethics-file-on-takeda-to-meet-friday-idUSKCN1P513E2019-01-12
The International Olympic Committee said its ethics committee has opened a file on the case and would meet on Friday adding that Takeda continues to enjoy the full presumption of innocence PositivePARIS The president of Japans Olympic Committee Tsunekazu Takeda is under formal investigation in France for suspected corruption related to Japans successful bid for the 2020 Olympic Games a French judicial source said on Friday http://www.reuters.com/places/africa/article/us-olympics-2020/france-investigates-japans-olympics-chief-on-suspicion-of-corruption-idUSKCN1P50TF2019-01-12





SentenceSentimentTitleUrlDate
Atsushi Takeda chief economist at Itochu Economic Research Institute said global headwinds suggest business spending is on the verge of leveling off NegativeTOKYO The Japanese economy contracted the most in over four years in the third quarter as companies slashed spending threatening to chill the investment outlook in 2019 as the exportreliant nation grapples with slowing global growth and trade frictions http://www.reuters.com/finance/markets/article/us-japan-economy-gdp/japans-economy-shrinks-most-in-four-years-as-global-risks-hit-business-spending-idUSKBN1O90282018-12-10
95 pounds on relief Takedas board had won its ninemonth battle to persuade shareholders of the merits of the tieup NegativeOSAKA Takeda Pharmaceutical http://www.reuters.com/finance/article/us-takeda-pharma-shire/takeda-clears-key-hurdle-as-investors-back-59-billion-shire-deal-idUSKBN1O40AD2018-12-06
A small group of Takeda investors including descendants of the companys founder had actively opposed the deal NegativeOSAKA Takeda Pharmaceutical http://www.reuters.com/finance/article/us-takeda-pharma-shire/takeda-clears-key-hurdle-as-investors-back-59-billion-shire-deal-idUSKBN1O40AD2018-12-06
Even with the acquisition of Shire some said Takeda will need to bolster its lineup of experimental therapies to compete in the longer term NegativeOSAKA Takeda Pharmaceutical http://www.reuters.com/finance/article/us-takeda-pharma-shire/takeda-clears-key-hurdle-as-investors-back-59-billion-shire-deal-idUSKBN1O40AD2018-12-06
I think is quite necessary for Takedas future but Shire is not the answer NegativeOSAKA Takeda Pharmaceutical http://www.reuters.com/finance/article/us-takeda-pharma-shire/takeda-clears-key-hurdle-as-investors-back-59-billion-shire-deal-idUSKBN1O40AD2018-12-06
Shares in Shire jumped 4 percent at the open then trimming gains to trade up 2 percent after shareholders of Japans Takeda approved the takeover of the Londonlisted pharmaceutical firm Negativea live blog on European stocks type in an Eikon news http://www.reuters.com/finance/markets/article/europe-stocks/european-stocks-drop-to-2-week-low-on-growth-trade-nerves-idUSL8N1YA1C42018-12-06
Takeda shares have fallen around 25 percent since the drugmaker revealed its interest in the acquisition in March NegativeOSAKA Takeda Pharmaceutical http://www.reuters.com/finance/article/us-takeda-pharma-shire/takeda-clears-key-hurdle-as-investors-back-59-billion-shire-deal-idUSKBN1O40AD2018-12-06
Takeda will be joining the ranks of the worlds top 10 drugmakers and gaining expertise in rare diseases through the deal the biggest overseas acquisition by a Japanese company PositiveOSAKA Takeda Pharmaceutical http://www.reuters.com/finance/article/us-takeda-pharma-shire/takeda-clears-key-hurdle-as-investors-back-59-billion-shire-deal-idUSKBN1O40AD2018-12-06
Glass Lewis said in a separate report that the strategic case is compelling for Takeda PositiveLONDON Two shareholder advisory firms have backed Takeda Pharmaceuticals http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-m-a-investors/investor-advisory-firms-back-takedas-62-billion-deal-for-shire-idUSKCN1NP1J12018-11-21
Japanese Takeda Pharmaceutical Company Limited to acquire Jersey biotechnology company Shire Nov PositiveBRUSSELS Nov 20 The following are mergers under review by the European Commission and a brief guide to the EU merger http://www.reuters.com/news/mediahttps://www.reuters.com/article/eu-ma/eu-mergers-and-takeovers-idUSL2N1XU0F02018-11-21
LONDON Two shareholder advisory firms have backed Takeda Pharmaceuticals NegativeLONDON Two shareholder advisory firms have backed Takeda Pharmaceuticals http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-m-a-investors/investor-advisory-firms-back-takedas-62-billion-deal-for-shire-idUSKCN1NP1J12018-11-21
However bringing a vaccine to market has proved difficult with drug companies including Japans Takeda Pharmaceutical and Inovio Pharmaceuticals Inc in the race NegativeA vaccine to prevent infections caused by the deadly mosquitoborne Zika virus induced immune response and was found to be safe in an early stage trial Emergent BioSolutions Inc and partner Valneva SE said on Monday http://www.reuters.com/news/health/article/us-emergent-bio-zika/emergent-valneva-zika-vaccine-clears-early-trial-idUSKCN1NO2KT2018-11-20
LONDON Banks law firms and other advisers stand to earn up to million in fees from Takeda Pharmaceuticals NegativeLONDON Banks law firms and other advisers stand to earn up to million in fees from Takeda Pharmaceuticals http://www.reuters.com/finance/article/us-shire-m-a-takeda-fees/takedas-shire-takeover-to-bring-963-million-fee-bonanza-idUSKCN1NH27E2018-11-13
Takeda has offered to divest Shires experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments NegativeLONDON Japans Takeda Pharmaceutical http://www.reuters.com/places/japan/article/us-takeda-pharma-shire/takeda-sets-vote-date-aims-to-close-62-billion-shire-deal-jan-8-idUSKCN1NH0RR2018-11-13
Takeda said on Monday it would hold an extraordinary general meeting of shareholders to vote on the transaction on Dec NegativeLONDON Japans Takeda Pharmaceutical http://www.reuters.com/places/japan/article/us-takeda-pharma-shire/takeda-sets-vote-date-aims-to-close-62-billion-shire-deal-jan-8-idUSKCN1NH0RR2018-11-13
The transaction is still awaiting approval from European regulators although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval PositiveLONDON Japans Takeda Pharmaceutical http://www.reuters.com/places/japan/article/us-takeda-pharma-shire/takeda-sets-vote-date-aims-to-close-62-billion-shire-deal-jan-8-idUSKCN1NH0RR2018-11-13
Weber a Frenchman and the first nonJapanese CEO of the company believes that buying Shire will accelerate Takedas growth and increase its international reach boosting earnings PositiveLONDON Japans Takeda Pharmaceutical http://www.reuters.com/places/japan/article/us-takeda-pharma-shire/takeda-sets-vote-date-aims-to-close-62-billion-shire-deal-jan-8-idUSKCN1NH0RR2018-11-13
Entyvio a treatment for Crohns disease and ulcerative colitis is Takedas biggestselling drug NegativeBRUSSELS Japanese drugmaker Takeda Pharmaceutical http://www.reuters.com/subjects/euro-zonehttps://www.reuters.com/article/us-shire-m-a-takeda-pharma-eu-exclusive/exclusive-takeda-to-win-eu-approval-for-62-billion-shire-deal-sources-idUSKCN1NE21B2018-11-10
Takeda has already secured unconditional clearance from regulators in the United States Japan China and Brazil PositiveBRUSSELS Japanese drugmaker Takeda Pharmaceutical http://www.reuters.com/subjects/euro-zonehttps://www.reuters.com/article/us-shire-m-a-takeda-pharma-eu-exclusive/exclusive-takeda-to-win-eu-approval-for-62-billion-shire-deal-sources-idUSKCN1NE21B2018-11-10
We are quite satisfied with our current progress at Takeda PositiveLONDON The boss of Japans Takeda Pharmaceutical http://www.reuters.com/places/japan/article/us-shire-m-a-takeda/takeda-ceo-confident-of-investor-backing-for-62-billion-shire-deal-idUSKCN1NA1WE2018-11-06
Weber however said he was confident he had persuaded Takeda shareholders sufficiently for the company to name an EGM date without specifying exactly when it would be held NeutralLONDON The boss of Japans Takeda Pharmaceutical http://www.reuters.com/places/japan/article/us-shire-m-a-takeda/takeda-ceo-confident-of-investor-backing-for-62-billion-shire-deal-idUSKCN1NA1WE2018-11-06
Japanese Takeda Pharmaceutical Company Limited to acquire Jersey biotechnology company Shire Sept PositiveBRUSSELS Oct 15 The following are mergers under review by the European Commission and a brief guide to the EU merger http://www.reuters.com/news/mediahttps://www.reuters.com/article/eu-ma/eu-mergers-and-takeovers-idUSL2N1WV05N2018-10-16
There is no change in Washingtons stance that it is demanding Japan cut its trade surplus with the said Atsushi Takeda chief economist at Itochu Economic Research Institute NegativeTOKYO Higher U.S. tariffs on Japanese car exports are less likely now the two nations agreed to start new trade talks economists said but most think U.S. trade friction with China and other economies will have a significant impact on Japan http://www.reuters.com/places/japan/article/us-japan-economy-poll/higher-u-s-tariffs-on-japanese-cars-less-likely-trade-war-posing-risk-reuters-poll-idUSKCN1MP0A32018-10-15
There is no vaccine for Zika yet though Japans Takeda Pharmaceutical and some other companies are trying to developing one NegativeMUMBAI At least 55 people have tested positive for the Zika virus in Indias tourist city of Jaipur up from 22 a week ago the local health department said on Sunday raising fears the virus is spreading just ahead of peak tourist season http://www.reuters.com/news/health/article/us-health-zika-india/zika-virus-cases-spike-in-indias-jaipur-as-peak-tourist-season-nears-idUSKCN1MO0HZ2018-10-14
6 whether to allow Japanese drugmaker Takeda Pharmaceuticals NeutralBRUSSELS EU antitrust regulators will decide by Nov http://www.reuters.com/places/japan/article/us-shire-m-a-takeda-eu/takedas-62-billion-shire-bid-faces-november-6-eu-antitrust-deadline-idUSKCN1M824W2018-09-29
HONG Japan volumes are set to break a 19yearold record and steal the spotlight in Asia this year from cooling Chinese deals led by blockbuster takeovers such as Takeda Pharmas PositiveHONG Japan volumes are set to break a 19yearold record and steal the spotlight in Asia this year from cooling Chinese deals led by blockbuster takeovers such as Takeda Pharmas http://www.reuters.com/places/japan/article/us-asia-m-a/japan-incs-global-push-drives-asia-mas-offsets-china-slowdown-idUSKCN1M72Z62018-09-28
Takeda soars after Daiwa raises rating PositiveAbout 155 points are cut by exdividend adjustment market http://www.reuters.com/finance/markets/article/japan-stocks-midday/nikkei-snaps-7-day-winning-streak-as-host-of-stocks-go-ex-dividend-idUSL4N1WC1H62018-09-26
Takeda Pharmaceutical Co Ltd said on Friday China approved its purchase of Shire Plc the latest regulator to clear the billion deal and bring the Japanese group closer to becoming a global top 10 drugmaker PositiveTakeda Pharmaceutical Co Ltd said on Friday China approved its purchase of Shire Plc the latest regulator to clear the billion deal and bring the Japanese group closer to becoming a global top 10 drugmaker http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-shire-m-a-takeda-pharma/takeda-gets-chinas-approval-for-62-billion-shire-purchase-idUSKCN1LU0SE2018-09-15
Takeda expects the deal to close in the first half of 2019 NegativeTakeda Pharmaceutical Co Ltd said on Friday China approved its purchase of Shire Plc the latest regulator to clear the billion deal and bring the Japanese group closer to becoming a global top 10 drugmaker http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-shire-m-a-takeda-pharma/takeda-gets-chinas-approval-for-62-billion-shire-purchase-idUSKCN1LU0SE2018-09-15
Takeda agreed to buy Shire in May in what would be the largest overseas purchase by a Japanese company NeutralJapans Takeda Pharmaceutical http://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma/takeda-weighs-sale-of-shires-eye-care-business-to-cut-debt-bloomberg-idUSKCN1LT0WO2018-09-14
The sale could help Takeda raise between billion and billion Bloomberg reported NeutralJapans Takeda Pharmaceutical http://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma/takeda-weighs-sale-of-shires-eye-care-business-to-cut-debt-bloomberg-idUSKCN1LT0WO2018-09-14
In May Takeda agreed to buy Londonlisted Shire for 45 NeutralJapans Takeda Pharmaceutical Co Ltd said on Wednesday it plans to shut its U.S. headquarters in Deerfield Illinois and move it to the greater Boston area following the closing of its Shire Plc acquisition http://www.reuters.com/places/japan/article/us-takeda-pharma-headquarters/takeda-to-pack-up-illinois-hq-nearly-1000-workers-to-be-affected-idUSKCN1LS2EY2018-09-13
It will also simplify our existing Takeda U.S. the spokeswoman said NeutralJapans Takeda Pharmaceutical Co Ltd said on Wednesday it plans to shut its U.S. headquarters in Deerfield Illinois and move it to the greater Boston area following the closing of its Shire Plc acquisition http://www.reuters.com/places/japan/article/us-takeda-pharma-headquarters/takeda-to-pack-up-illinois-hq-nearly-1000-workers-to-be-affected-idUSKCN1LS2EY2018-09-13
Japans Takeda Pharmaceutical Co Ltd said on Wednesday it plans to shut its U.S. headquarters in Deerfield Illinois and move it to the greater Boston area following the closing of its Shire Plc acquisition NegativeJapans Takeda Pharmaceutical Co Ltd said on Wednesday it plans to shut its U.S. headquarters in Deerfield Illinois and move it to the greater Boston area following the closing of its Shire Plc acquisition http://www.reuters.com/places/japan/article/us-takeda-pharma-headquarters/takeda-to-pack-up-illinois-hq-nearly-1000-workers-to-be-affected-idUSKCN1LS2EY2018-09-13
This move while difficult will allow closer collaboration across Takeda to best position our future pipeline for success NeutralJapans Takeda Pharmaceutical Co Ltd said on Wednesday it plans to shut its U.S. headquarters in Deerfield Illinois and move it to the greater Boston area following the closing of its Shire Plc acquisition http://www.reuters.com/places/japan/article/us-takeda-pharma-headquarters/takeda-to-pack-up-illinois-hq-nearly-1000-workers-to-be-affected-idUSKCN1LS2EY2018-09-13
The billion Shire deal which will send Takedas debt levels sharply higher is still awaiting the nod from regulators in EU China and elsewhere NegativeThe company said its outlook for the year including its oncology franchise that it has separately agreed to sell was unchanged http://www.reuters.com/places/japan/article/us-shire-results/shire-profit-edges-higher-ahead-of-takeda-sale-idUSKBN1KL1J72018-07-31
Chief Executive Christophe Weber has been working to persuade investors about the deal which has weighed heavily on Takedas stock price Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/takeda-gets-key-u-s-regulatory-approval-to-buy-shire-idUSKBN1K00K82018-07-10
It expects the deal to close in the first half on 2019 Takeda said Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/takeda-gets-key-u-s-regulatory-approval-to-buy-shire-idUSKBN1K00K82018-07-10
Takeda has received unconditional clearance from the United States Federal Trade Commission for the Shire deal the drugmaker said Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/takeda-gets-key-u-s-regulatory-approval-to-buy-shire-idUSKBN1K00K82018-07-10
Takeda shares closed flat on Tuesday while the statement was released after trading hours Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/takeda-gets-key-u-s-regulatory-approval-to-buy-shire-idUSKBN1K00K82018-07-10
The Shire deal would turn Takeda into one of the worlds largest drugmakers Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/takeda-gets-key-u-s-regulatory-approval-to-buy-shire-idUSKBN1K00K82018-07-10
Takeda which was founded in Osaka in 1781 opened its new global headquarters in Tokyo this week Negativehttp://www.reuters.com/places/japan/article/us-takeda-strategy/japans-takeda-to-sell-osaka-headquarters-could-raise-60-billion-yen-nikkei-idUSKBN1JV1112018-07-05
Takedas board has said such a requirement would damage the companys competitiveness Negativehttp://www.reuters.com/finance/article/us-takeda-agm/takeda-shareholder-group-proposal-fails-to-pass-at-agm-idUSKBN1JO0DU2018-06-28
Takedas shares are nevertheless down 18 percent at 4524 yen since the company first said at the end of March it was considering bidding for Shire Negativehttp://www.reuters.com/finance/article/us-takeda-agm/takeda-shareholders-bin-proposal-from-anti-shire-group-only-10-percent-in-favor-idUSKBN1JO0DU2018-06-28
The 130 membergroup formed by exTakeda employees told Reuters earlier this month it did not expect its proposal to pass on Thursday Negativehttp://www.reuters.com/finance/article/us-takeda-agm/takeda-shareholders-bin-proposal-from-anti-shire-group-only-10-percent-in-favor-idUSKBN1JO0DU2018-06-28
The Shire deal would turn Takeda into one of the worlds largest drugmakers but the group says it would require taking on too much financial risk Negativehttp://www.reuters.com/finance/article/us-takeda-agm/takeda-shareholders-bin-proposal-from-anti-shire-group-only-10-percent-in-favor-idUSKBN1JO0DU2018-06-28
The move would turn Takeda into one of the worlds most indebted drugmakers though Weber has insisted he can deliver savings to make the deal a big winner for shareholders Negativehttp://www.reuters.com/finance/article/us-takeda-agm/takeda-shareholders-bin-proposal-from-anti-shire-group-only-10-percent-in-favor-idUSKBN1JO0DU2018-06-28
Takeda Chief Executive Christophe Weber has expressed confidence shareholders will vote in favor of the deal Positivehttp://www.reuters.com/finance/article/us-shire-m-a-takeda/takeda-shareholder-group-aims-to-block-62-billion-shire-deal-idUSKBN1J71382018-06-11
The 130 member group formed by exTakeda employees holds one percent of the drugmakers shares and needs to secure a third of shareholder votes Negativehttp://www.reuters.com/finance/article/us-shire-m-a-takeda/takeda-shareholder-group-aims-to-block-62-billion-shire-deal-idUSKBN1J71382018-06-11
The family owns about 10 percent of Takeda shares people familiar with the matter told Reuters Neutralhttp://www.reuters.com/finance/article/us-shire-m-a-takeda/takeda-shareholder-group-aims-to-block-62-billion-shire-deal-idUSKBN1J71382018-06-11
The group includes members of the founding Takeda family Nikkan Yakugyo reported last month Neutralhttp://www.reuters.com/finance/article/us-shire-m-a-takeda/takeda-shareholder-group-aims-to-block-62-billion-shire-deal-idUSKBN1J71382018-06-11
Hemlibra will shake up the market and pose a threat to established players reliant on factor replacement therapies notably Shire which has agreed to be acquired by Takeda Pharmaceutical Negativehttp://www.reuters.com/news/health/article/us-roche-haemophilia/roche-drug-dramatically-reduces-bleeds-in-key-hemophilia-tests-idUSKCN1IM0N72018-05-21
Takeda has forecast annual cost synergies of at least Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-ceo-focus/takeda-ceo-prescribes-surgical-rd-cuts-after-62-billion-shire-deal-idUSKCN1II1P52018-05-17
The real test will come later this year when Weber will learn if he has secured the necessary twothirds support needed from Takeda shareholders and threequarters backing from Shire investors Neutralhttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-ceo-focus/takeda-ceo-prescribes-surgical-rd-cuts-after-62-billion-shire-deal-idUSKCN1II1P52018-05-17
The ruling covers three active substances imidacloprid developed by Bayer CropScience clothianidin developed by Takeda Chemical Industries and Bayer CropScience as well as Syngentas thiamethoxam Negativehttp://www.reuters.com/subjects/euro-zonehttps://www.reuters.com/article/us-eu-environment-bees/eu-court-upholds-insecticide-ban-to-protect-bees-idUSKCN1II0WU2018-05-17
Takeda Pharmaceutical fell 2 Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-close/nikkei-drops-after-trump-quits-iran-nuclear-deal-toyota-shines-after-earnings-idUSL3N1SG2QI2018-05-09
6 percent after Takeda Pharmaceutical said it agreed to buy the group for 45 Negativehttp://www.reuters.com/finance/markets/article/europe-stocks/update-2-italian-stocks-underperform-europe-as-election-worries-bite-idUSL8N1SF2CW2018-05-08
678 Takeda ADSs for each share the companies said Neutralhttp://www.reuters.com/finance/markets/article/shire-ma-takeda/refile-japans-takeda-agrees-62-billion-takeover-of-shire-idUSASO0004I62018-05-08
Buying Shire is a big financial stretch for Takeda but Weber believes it will generate substantial cash flow enabling the enlarged group to pay down its borrowings quickly Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-clinches-62-billion-deal-to-buy-drugmaker-shire-idUSKBN1I90IC2018-05-08
During Tokyo trade Takeda surged 4 percent and was the third most traded stock by turnover as investors had anticipated an official announcement of the deal Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-close/nikkei-rises-as-banks-rally-takeda-up-ahead-of-acquisition-news-idUSL3N1SF2TV2018-05-08
LONDON May 8 Takeda Pharma agreed to buy Londonlisted Shire for 46 billion pounds Negativehttp://www.reuters.com/finance/markets/article/shire-ma-takeda/refile-japans-takeda-agrees-62-billion-takeover-of-shire-idUSASO0004I62018-05-08
Prior to his arrival Takeda bought Nycomed for billion in 2011 in its previous biggest deal Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-m-a-takeda/japans-takeda-clinches-62-billion-shire-deal-as-pharma-ma-rolls-on-idUSKBN1I90IC2018-05-08
Shire added 4 percent after Takeda Pharmaceutical said it agreed to buy the group for 45 Negativehttp://www.reuters.com/finance/markets/article/europe-stocks/update-1-european-shares-retreat-as-election-worries-hit-italy-idUSL8N1SF2CW2018-05-08
Shire said last month it would be willing to recommend an offer from Takeda after it rejected four previous approaches Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-agrees-to-62-billion-takeover-of-shire-idUSKBN1I90IC2018-05-08
TOKYO May 8 Japans Nikkei share average rose on Tuesday as banking stocks rallied while Takeda Pharmaceutical climbed ahead of news the drugmaker had agreed to buy Londonlisted Shire for Positivehttp://www.reuters.com/finance/markets/article/japan-stocks-close/nikkei-rises-as-banks-rally-takeda-up-ahead-of-acquisition-news-idUSL3N1SF2TV2018-05-08
TOKYO May 8 Japans Nikkei share average rose on Tuesday as tech shares rallied and Takeda Pharmaceutical jumped after a report the drugmaker will make a formal offer to buy Shire for billion Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-midday/nikkei-rises-helped-by-tech-stocks-banks-takedas-shire-offer-idUSL3N1SF1LH2018-05-08
Takeda Pharma agreed to buy Londonlisted Shire for 46 billion pounds Negativehttp://www.reuters.com/finance/markets/article/britain-stocks-factors/update-1-uk-stocks-factors-to-watch-on-may-8-idUSL3N1SF2VQ2018-05-08
Takeda Pharmaceutical agreed to buy Londonlisted Shire for 45 Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-clinches-62-billion-deal-to-buy-drugmaker-shire-idUSKBN1I90IC2018-05-08
Takeda Pharmaceutical and Shire announced after the Tokyo market close the acquisition which includes a combination of cash and shares Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-close/nikkei-rises-as-banks-rally-takeda-up-ahead-of-acquisition-news-idUSL3N1SF2TV2018-05-08
Takeda Pharmaceutical gained 2 percent and was the third most traded stock in turnover after trading in negative territory Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-midday/nikkei-rises-helped-by-tech-stocks-banks-takedas-shire-offer-idUSL3N1SF1LH2018-05-08
Takeda expects substantial cost synergies of at least Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-agrees-to-62-billion-takeover-of-shire-idUSKBN1I90IC2018-05-08
Takeda later said negotiations are continuing and it will make an announcement when it reaches an agreement Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-midday/nikkei-rises-helped-by-tech-stocks-banks-takedas-shire-offer-idUSL3N1SF1LH2018-05-08
Takeda said it would maintain its global headquarters in Japan and evaluate consolidating Shires operations into Takedas in the Boston area Switzerland and Singapore Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-m-a-takeda/japans-takeda-clinches-62-billion-shire-deal-as-pharma-ma-rolls-on-idUSKBN1I90IC2018-05-08
Takeda was advised by Evercore J.P. Morgan and Nomura while Shire worked with Citi Goldman Sachs and Morgan Stanley Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-clinches-62-billion-deal-to-buy-drugmaker-shire-idUSKBN1I90IC2018-05-08
The transaction also needs twothirds approval from Takeda shareholders Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-m-a-takeda/japans-takeda-clinches-62-billion-shire-deal-as-pharma-ma-rolls-on-idUSKBN1I90IC2018-05-08
Weber became Takedas first nonJapanese CEO in 2015 and has been hunting for acquisitions to make the company more global and reduce its exposure to a mature Japanese pharmaceutical market Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-clinches-62-billion-deal-to-buy-drugmaker-shire-idUSKBN1I90IC2018-05-08
At the same time Takeda also needs twothirds shareholder support to issue the new shares needed for the acquisition a potential flashpoint with skeptical investors Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-results/overshadowed-by-takeda-bid-shire-reports-solid-start-to-year-idUSKBN1HX1RN2018-04-27
Chief Executive Flemming Ornskov said Shires board would engage in talks with Takeda on the terms of a possible offer and both parties would conduct due diligence Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-results/overshadowed-by-takeda-bid-shire-reports-solid-start-to-year-idUSKBN1HX1RN2018-04-27
Takedas falling share price has already reduced the value of the cashandshares deal to around Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-results/overshadowed-by-takeda-bid-shire-reports-solid-start-to-year-idUSKBN1HX1RN2018-04-27
Yen capped sterling helped by Takedas bid to buy Shire Negativehttp://www.reuters.com/finance/markets/article/global-forex/forex-dollar-at-3-1-2-month-high-on-elevated-yields-euro-soft-after-ecb-idUSL3N1S40AM2018-04-27
4 percent after saying that it would recommend Takedas sweetened billion bid offer to shareholders Negativehttp://www.reuters.com/finance/markets/article/europe-stocks/kering-credit-suisse-earnings-fail-to-boost-european-shares-idUSL8N1S21S22018-04-25
A TakedaShire transaction would be by far the biggest Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-deal-exclusiv/shire-says-willing-to-recommend-takedas-64-billion-offer-to-shareholders-idUSKBN1HV2P42018-04-25
A deal would significantly boost Takedas position in gastrointestinal disorders neuroscience and rare diseases including a blockbuster hemophilia franchise Positivehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-deal-exclusiv/shire-says-willing-to-recommend-takedas-64-billion-offer-to-shareholders-idUSKBN1HV2P42018-04-25
Acquiring Shire would transform Takedas position in rare diseases gastrointestinal disorders and neuroscience where Shire is a leader in ADHD drugs Negativehttp://www.reuters.com/places/japan/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
Any deal is subject to the resolution of several issues including completion of due diligence by Shire on Takeda the Dublinbased company said Neutralhttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-deal-exclusiv/shire-says-willing-to-recommend-takedas-64-billion-offer-to-shareholders-idUSKBN1HV2P42018-04-25
Complicating matters is that chief financial officer Costa Saroukos who had overseen the finances of Takedas Europe and Canada businesses only started in his new role this month Negativehttp://www.reuters.com/places/japan/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
Feldinger who worked at Nycomed and Takeda before becoming a consultant said the union of the two companies had stalled until Weber took charge Neutralhttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
Hasegawa was the architect of Takedas shift Neutralhttp://www.reuters.com/places/japan/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
His pursuit of foreigners to fill Takedas executive ranks cut against the grain of Japans insular corporate world Neutralhttp://www.reuters.com/places/japan/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
LONDON April 25 European shares declined on Wednesday in early deals as worries over rising bond yields trumped a slew of wellreceived earnings updates from Kering and Credit Suisse while Shire bounced after accepting an improved offer from Takeda Negativehttp://www.reuters.com/finance/markets/article/europe-stocks/kering-credit-suisse-earnings-fail-to-boost-european-shares-idUSL8N1S21S22018-04-25
LONDON European shares declined on Wednesday in early deals as worries over rising bond yields trumped a slew of wellreceived earnings updates from Kering and Credit Suisse while Shire slipped after accepting an improved offer from Takeda Negativehttp://www.reuters.com/finance/markets/article/us-europe-stocks/kering-credit-suisse-earnings-fail-to-boost-european-shares-idUSKBN1HW0QK2018-04-25
Peter Feldinger who worked at Nycomed and Takeda before becoming a consultant said the union of the two companies had stalled until Weber took charge Neutralhttp://www.reuters.com/places/japan/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
Rare disease drug maker Shire Plc said on Tuesday it was willing to recommend a sweetened billion offer from Japans Takeda Pharmaceutical Co to shareholders in what could be the biggest acquisition of a drug company this year Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-deal-exclusiv/shire-says-willing-to-recommend-takedas-64-billion-offer-to-shareholders-idUSKBN1HV2P42018-04-25
Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened billion offer from Japans Takeda Pharmaceutical Co to shareholders in what would be the biggest acquisition of a drug company this year Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-deal-exclusiv/shire-willing-to-back-64-billion-takeda-bid-market-signals-doubts-idUSKBN1HV2P42018-04-25
Shire to recommend improved Takeda bid to shareholders prices adds Positivehttp://www.reuters.com/finance/markets/article/europe-stocks/update-2-european-shares-fall-as-bond-yields-rise-metals-prices-slide-idUSL8N1S22862018-04-25
Shire would transform Takedas position in rare diseases gastrointestinal disorders and neuroscience where Shire is a leader in ADHD drugs Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
Some investors worry that Takeda with only Neutralhttp://www.reuters.com/places/japan/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
TOKYO April 25 Japanese stocks slipped on Wednesday as weakness on Wall Street soured risk sentiment while the spotlight fell on Takeda Pharmaceutical which stumbled after it sweetened its takeover bid for Shire to 46 billion pounds Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-close/nikkei-falls-takeda-dives-on-shire-bid-construction-machinery-makers-underperform-idUSL3N1S22KM2018-04-25
TOKYO April 25 Japanese stocks slipped on Wednesday morning as weakness on Wall Street soured risk sentiment while the spotlight fell on Takeda Pharmaceutical which stumbled after it sweetened its takeover bid for Shire to 46 billion pounds Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-midday/nikkei-falters-takeda-dives-over-9-pct-on-shire-takeover-bid-idUSL3N1S21J22018-04-25
TOKYO Takeda Pharmaceutical Co shares fell more than 5 percent in early trade on Wednesday following news it had sweetened its acquisition offer for Londonlisted drugmaker Shire Plc to 46 billion pounds Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-takeda-pharma-stocks/takeda-shares-slide-5-percent-after-revised-proposal-for-shire-idUSKBN1HW0112018-04-25
Takeda declined to make Weber or Hasegawa available for this story Neutralhttp://www.reuters.com/places/japan/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
Takeda dived 7 Neutralhttp://www.reuters.com/finance/markets/article/japan-stocks-close/nikkei-falls-takeda-dives-on-shire-bid-construction-machinery-makers-underperform-idUSL3N1S22KM2018-04-25
Takeda fell sharply losing as much as 9 Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-midday/nikkei-falters-takeda-dives-over-9-pct-on-shire-takeover-bid-idUSL3N1S21J22018-04-25
The latest development first reported by Reuters comes after Londonlisted Shire rejected four previous offers from Takeda Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-deal-exclusiv/shire-willing-to-back-64-billion-takeda-bid-market-signals-doubts-idUSKBN1HV2P42018-04-25
The latest development first reported by Reuters comes after Londonlisted Shire rejected four previous offers from Takeda and will leave Shire shareholders owning half of the combined company Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-deal-exclusiv/shire-says-willing-to-recommend-takedas-64-billion-offer-to-shareholders-idUSKBN1HV2P42018-04-25
The surprise decision to appoint Weber then the companys chief operating officer as his successor led to open revolt among some of Takedas old guard Negativehttp://www.reuters.com/places/japan/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
Weber who became Takedas first nonJapanese CEO in 2015 has said publicly it was looking for acquisitions to reduce its exposure to a mature Japanese pharmaceutical market Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-deal-exclusiv/shire-says-willing-to-recommend-takedas-64-billion-offer-to-shareholders-idUSKBN1HV2P42018-04-25
While questions remain over whether Takeda overpaid for its past acquisitions drugs on the market as a result are feeding stronger recent results Neutralhttp://www.reuters.com/places/japan/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
While this offer represents a solid improvement over Takedas third bid percent we still wonder if it is enough to satisfy Shire said Jefferies analyst David Steinberg Neutralhttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-deal-exclusiv/shire-willing-to-back-64-billion-takeda-bid-market-signals-doubts-idUSKBN1HV2P42018-04-25
investors worry that Takeda with only Neutralhttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
matters is that chief financial officer Costa Saroukos who had overseen the finances of Takedas Europe and Canada businesses only started in his new role this month Neutralhttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
pursuit of foreigners to fill Takedas executive ranks cut against the grain of Japans insular corporate world Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
questions remain over whether Takeda overpaid for its past acquisitions drugs on the market as a result are feeding stronger recent results Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
surprise decision to appoint Weber then the companys chief operating officer as his successor led to open revolt among some of Takedas old guard Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUSKBN1HW11A2018-04-25
Londonlisted drugmaker Shire Plc and Japans Takeda Pharmaceutical Co Ltd plan to announce a preliminary deal on Wednesday after the latter sweetened its billion acquisition offer people familiar with the matter said Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-deal-exclusiv/exclusive-shire-takeda-reach-breakthrough-in-deal-talks-sources-idUSKBN1HV2P42018-04-24
Shire focuses on drugs to treat rare diseases and attention deficit hyperactivity disorder and a takeover would catapult Takeda into the top ranks of global drugmakers Positivehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma/shire-receives-new-bid-from-takeda-as-takeover-deadline-looms-idUSKBN1HV1H12018-04-24
Based on Takedas current market value Shire shareholders would own approximately 49 percent of the enlarged company should the latest proposal be accepted Neutralhttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-sweetens-62-billion-shire-offer-idUSKBN1HR00T2018-04-21
Buying Shire would be the largest ever overseas acquisition by a Japanese company and propel Takeda led by Frenchman Christophe Weber into the top ranks of global drugmakers Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-sweetens-62-billion-shire-offer-idUSKBN1HR00T2018-04-21
Japans Takeda Pharmaceutical Co Ltd is considering raising its cashandstock bid for Londonlisted drug maker Shire Plc to approximately 47 pounds per share or more people familiar with the matter said on Friday Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma/takeda-weighs-raising-shire-bid-to-more-than-47-stg-share-sources-idUSKBN1HR21X2018-04-21
Japans Takeda Pharmaceutical nudged up its offer for Shire to 44 Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-sweetens-62-billion-shire-offer-idUSKBN1HR00T2018-04-21
Takeda and Shire did not immediately respond to requests for comment Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma/takeda-weighs-raising-shire-bid-to-more-than-47-stg-share-sources-idUSKBN1HR21X2018-04-21
The latest proposal is 7 percent above Takedas first offer and 58 percent above Londonlisted Shires share price prior to any takeover speculation the Japanese firm said Positivehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-sweetens-62-billion-shire-offer-idUSKBN1HR00T2018-04-21
Several analysts said Takeda Japans biggest drugmaker by sales will need to substantially raise the cash component of its offer make it attractive to Shire shareholders Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-shares-drop-as-investors-fret-over-shire-pursuit-idUSKBN1HR00T2018-04-20
Takeda has room to raise its cash offer but we do not see a lot of Daiwa Securities analyst Kazuaki Hashiguchi wrote in a client note Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-shares-drop-as-investors-fret-over-shire-pursuit-idUSKBN1HR00T2018-04-20
Takedas shares closed down 4 Neutralhttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-shares-drop-as-investors-fret-over-shire-pursuit-idUSKBN1HR00T2018-04-20
Under British takeover rules Takeda has until April 25 to make a firm offer or walk away Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda/japans-takeda-shares-drop-as-investors-fret-over-shire-pursuit-idUSKBN1HR00T2018-04-20
A spokesman for Takeda declined to comment and Shire did not reply to a request for comment Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-m-a-takeda-pharma/takeda-makes-61-billion-bid-for-drugmaker-shire-sources-idUSKBN1HQ1C82018-04-19
A takeover would be transformational for Takeda which has a market value of about Neutralhttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-m-a-takeda-pharma/takeda-makes-61-billion-bid-for-drugmaker-shire-sources-idUSKBN1HQ1C82018-04-19
Based on Takedas market capitalization Shire shareholders would end up owning approximately 51 percent of the enlarged group Shire noted Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-bid/shire-rejects-63-billion-takeda-bid-as-allergan-drops-pursuit-idUSKBN1HQ1PN2018-04-19
Botox maker Allergan Plc is in talks to acquire Shire Plc competing against Japans Takeda Pharmaceutical Co Ltd for the Londonlisted drugmaker two sources familiar with the matter said on Thursday Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-allergan-exclusive/exclusive-allergan-in-talks-to-acquire-shire-competing-against-takeda-sources-idUSKBN1HQ2032018-04-19
Buying would be the largest ever overseas acquisition by a Japanese company and propel Takeda led by Frenchman Christophe Weber into the top ranks of global drugmakers Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-bid/shire-rejects-63-billion-takeda-bid-as-allergan-drops-pursuit-idUSKBN1HQ1PN2018-04-19
Japans Takeda Pharmaceutical the United States National Institute of Health and Brazils Butantan Institute are developing rival products Negativehttp://www.reuters.com/news/health/article/us-dengue-sanofi-who/who-recommends-testing-before-use-of-sanofis-dengue-vaccine-idUSKBN1HQ23R2018-04-19
Shire confirmed it had received three conditional proposals from Takeda but said they significantly undervalued the companys growth prospects and drugs in development Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-bid/shire-rejects-63-billion-takeda-bid-as-allergan-drops-pursuit-idUSKBN1HQ1PN2018-04-19
Shire confirmed that it had received three conditional proposals from Takeda Neutralhttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-bid/takeda-in-talks-with-shire-after-61-billion-bid-rejected-idUSKBN1HQ1PN2018-04-19
Takeda confirmed last month it was considering an offer for Shire which sells treatments for rare diseases and attention deficit disorder Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-m-a-takeda-pharma/takeda-makes-61-billion-bid-for-drugmaker-shire-sources-idUSKBN1HQ1C82018-04-19
Takeda was subsequently notified that the board of Shire had rejected its proposal Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-bid/takeda-in-talks-with-shire-after-61-billion-bid-rejected-idUSKBN1HQ1PN2018-04-19
Under UK takeover rules Takeda has until April 25 to make a firm offer or walk away after it said last month it was considering a bid Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-bid/shire-rejects-63-billion-takeda-bid-as-allergan-drops-pursuit-idUSKBN1HQ1PN2018-04-19
A Takeda spokesman declined to comment Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-servier/shire-sells-cancer-drugs-to-servier-for-2-4-billion-as-takeda-circles-idUSKBN1HN0P82018-04-16
April 16 The following bids mergers acquisitions and disposals were reported by 1000 GMT on Shire the Londonlisted rare diseases specialist that is a potential takeover target for Japans Takeda Pharmaceutical is selling its oncology business to unlisted French drugmaker Servier for Negativehttp://www.reuters.com/finance/markets/article/deals-day/deals-of-the-day-mergers-and-acquisitions-idUSL3N1RT41O2018-04-16
LONDON Shire the Londonlisted rare diseases specialist that is a potential takeover target for Japans Takeda Pharmaceutical is selling its oncology business to unlisted French drugmaker Servier for Negativehttp://www.reuters.com/news/health/article/us-shire-m-a-servier/shire-sells-cancer-drugs-to-servier-for-2-4-billion-as-takeda-circles-idUSKBN1HN0P82018-04-16
Two sources with direct knowledge of the matter said last week that Takeda had sounded out its major creditors for loans to fund a potential Shire bid Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-servier/shire-sells-cancer-drugs-to-servier-for-2-4-billion-as-takeda-circles-idUSKBN1HN0P82018-04-16
Under UK takeover regulations Takeda has until April 25 to announce whether or not it will bid for Shire which has a market value of around billion Negativehttp://www.reuters.com/news/health/article/us-shire-m-a-servier/shire-sells-cancer-drugs-to-servier-for-2-4-billion-as-takeda-circles-idUSKBN1HN0P82018-04-16
Under UK takeover rules Takeda has until April 25 to announce whether or not it will bid for Shire which has a market value of around billion Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-servier/shire-sells-cancer-drugs-to-servier-for-2-4-billion-as-takeda-circles-idUSKBN1HN0P82018-04-16
Kyodo News reported earlier that Takeda was looking for loans of several trillion yen of billions of in total from multiple banks Neutralhttp://www.reuters.com/finance/article/us-shire-m-a-takeda-pharma/takeda-sounds-out-banks-for-loans-as-it-moves-towards-shire-bid-sources-idUSKBN1HJ0D92018-04-12
Takeda has sounded out creditors including its main bank Sumitomo Mitsui Banking Corp the two sources said on Thursday declining to be identified as the matter was confidential Negativehttp://www.reuters.com/finance/article/us-shire-m-a-takeda-pharma/takeda-sounds-out-banks-for-loans-as-it-moves-towards-shire-bid-sources-idUSKBN1HJ0D92018-04-12
Takeda shares ended down 1 Neutralhttp://www.reuters.com/finance/article/us-shire-m-a-takeda-pharma/takeda-sounds-out-banks-for-loans-as-it-moves-towards-shire-bid-sources-idUSKBN1HJ0D92018-04-12
Under UK takeover rules Takeda has until April 25 to decide whether to make a bid Neutralhttp://www.reuters.com/finance/article/us-shire-m-a-takeda-pharma/takeda-sounds-out-banks-for-loans-as-it-moves-towards-shire-bid-sources-idUSKBN1HJ0D92018-04-12
A second investor said confidence in Ornskov had been eroded increasing the likelihood of a deal if Takeda came up with a fair price Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-m-a-takeda-pharma/hopes-rise-for-shire-sale-as-takeda-ceo-discusses-case-for-deal-idUSKCN1HC1WF2018-04-06
During the meeting Weber discussed the strategic case for buying Shire and addressed concerns about the size of such an acquisition which Takeda first announced it was considering last week Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-m-a-takeda-pharma/hopes-rise-for-shire-sale-as-takeda-ceo-discusses-case-for-deal-idUSKCN1HC1WF2018-04-06
The briefing by Takeda Chief Executive Christophe Weber for analysts fueled a 4 percent jump in Shire shares valuing the company at around billion or billion more than Takeda Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-m-a-takeda-pharma/hopes-rise-for-shire-sale-as-takeda-ceo-discusses-case-for-deal-idUSKCN1HC1WF2018-04-06
But some analysts also doubted whether Shires treatments for haemophilia and other rare diseases would benefit Takeda and thought that any deal should be more targeted Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-shares/merits-of-any-takeda-bid-for-shire-questioned-shares-slide-idUSKBN1H50252018-03-29
However Takeda fell 7 Neutralhttp://www.reuters.com/finance/markets/article/japan-stocks-close/nikkei-rises-helped-by-retail-food-stocks-takeda-stumbles-idUSL3N1RB2UY2018-03-29
However Takeda fell more than 6 percent after it said it was at a preliminary and exploratory of considering a bid for Shire adding it had not approached Shires board Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-midday/nikkei-rises-as-weak-yen-lifts-sentiment-takeda-stumbles-idUSL3N1RB1PC2018-03-29
Investors are worried that the deal would cause a big debt burden on Takeda whose market capitalisation is smaller than said a market strategist in Tokyo Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-close/nikkei-rises-helped-by-retail-food-stocks-takeda-stumbles-idUSL3N1RB2UY2018-03-29
Investors are worried that the deal would cause a big debt burden on Takeda whose market capitalization is smaller than said a market strategist in Tokyo Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-midday/nikkei-rises-as-weak-yen-lifts-sentiment-takeda-stumbles-idUSL3N1RB1PC2018-03-29
Japans largest drugmaker Takeda Pharmaceutical is considering a bid for Londonlisted rare disease specialist Shire that could top billion and spark another takeover battle in the dealhungry pharma industry Negativehttp://www.reuters.com/finance/markets/article/britain-stocks-factors/update-1-uk-stocks-factors-to-watch-on-march-29-idUSL3N1RB3412018-03-29
Shire which sells treatments for rare diseases and attention deficit disorder said it noted Takedas statement and confirmed it had not received an approach Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-close/nikkei-rises-helped-by-retail-food-stocks-takeda-stumbles-idUSL3N1RB2UY2018-03-29
TOKYO March 29 Japans Nikkei share average rose on Thursday helped by gains in domesticdemand stocks but Takeda Pharmaceutical stumbled after it said it was considering a bid for Londonlisted Shire that could top billion Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-close/nikkei-rises-helped-by-retail-food-stocks-takeda-stumbles-idUSL3N1RB2UY2018-03-29
TOKYO March 29 Japans Nikkei share average rose on Thursday morning as a weaker yen lifted risk sentiment but Takeda Pharmaceutical stumbled after it said it was considering a bid for Londonlisted Shire that could top billion Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-midday/nikkei-rises-as-weak-yen-lifts-sentiment-takeda-stumbles-idUSL3N1RB1PC2018-03-29
Takedas potential bid for Shire most of whose employees are based in North America immediately stoked expectations for another takeover battle in the dealhungry pharma industry Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-shares/merits-of-any-takeda-bid-for-shire-questioned-shares-slide-idUSKBN1H50252018-03-29
That similarity in size had raised the question whether the damage to Takedas finances would be worth the boost to its portfolio and pipeline Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma-shares/merits-of-any-takeda-bid-for-shire-questioned-shares-slide-idUSKBN1H50252018-03-29
It said it would also balance Takedas geographic focus to align with the market opportunity in the United States Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma/japans-takeda-weighs-bid-for-drugmaker-shire-idUSKBN1H41982018-03-28
Shire said it noted Takedas statement and confirmed it had not received an approach Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma/drugmaker-shire-soars-as-japans-takeda-considers-bid-idUSKBN1H41982018-03-28
Takeda Japans largest drugmaker by sales focuses its research on developing treatments for cancer and diseases of the digestive and nervous systems Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma/japans-takeda-weighs-bid-for-drugmaker-shire-idUSKBN1H41982018-03-28
Takeda could face competition Positivehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma/japans-takeda-weighs-bid-for-drugmaker-shire-idUSKBN1H41982018-03-28
Takeda said a deal for Shire would create a global biopharmaceutical leader and strengthen its presence in the treatment of rare diseases and the oncology gastrointestinal and neuroscience sectors Negativehttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma/japans-takeda-weighs-bid-for-drugmaker-shire-idUSKBN1H41982018-03-28
Takeda said it had not approached Shires board Neutralhttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma/drugmaker-shire-soars-as-japans-takeda-considers-bid-idUSKBN1H41982018-03-28
The statement came after Takedas shares had closed 1 Neutralhttp://www.reuters.com/places/japan/article/us-shire-m-a-takeda-pharma/drugmaker-shire-soars-as-japans-takeda-considers-bid-idUSKBN1H41982018-03-28
Drugmakers lost ground with Takeda Pharmaceutical shedding 1 Negativehttp://www.reuters.com/finance/markets/article/japan-stocks-close/nikkei-falls-as-tech-shares-weak-investors-cautious-before-holiday-and-fed-idUSL3N1R22MX2018-03-20
2 percent and Takeda Pharmaceutical rose 2 NeutralTOKYO Feb 27 Nikkei share average soared to more than a threeweek high after large market capitalization stocks in the Core 30 stocks led the gains while Inpex attracted buying after it won a stake in an Abu Dhabi oil concession http://www.reuters.com/finance/markets/article/japan-stocks-midday/nikkei-soars-to-more-than-3-week-high-topix-core-30-stocks-gain-ground-idUSL4N1QH1LX2018-02-27
0 percent and Takeda Pharmaceutical added 1 NegativeTOKYO Feb 8 Nikkei share average edged higher on Thursday as buyers looked for bargains on shares which were beaten down heavily early in the week but gains were cautious as investors feared further wild volatility in global markets http://www.reuters.com/finance/markets/article/japan-stocks-midday/nikkei-rises-on-bargain-hunting-but-investors-edgy-after-wild-sell-off-idUSL4N1PY1L52018-02-08
9 percent and Takeda Pharmaceutical added 1 PositiveTOKYO Feb 8 Nikkei share average rose on Thursday as buyers looked for bargains on shares which were beaten down heavily early in the week http://www.reuters.com/finance/markets/article/japan-stocks-close/nikkei-rises-as-investors-chase-bargains-automakers-drugmakers-lead-idUSL4N1PY2P12018-02-08
CHICAGO New dengue vaccines being developed by Takeda Pharmaceuticals Co Ltd and US government scientists are poised to provide a safer alternative to Dengvaxia according to vaccine experts because they already take into account some of the issues that sidelined the product last year NegativeCHICAGO New dengue vaccines being developed by Takeda Pharmaceuticals Co Ltd and U.S. government scientists are poised to provide a safer alternative to Sanofiís Dengvaxia according to vaccine experts because they already take into account some of the issues that sidelined the product last yearhttp://www.reuters.com/finance/article/us-sanofi-dengue-competitors/how-sanofis-setback-could-lead-to-better-dengue-vaccines-idUSKBN1FI0FY2018-01-29
Nextgeneration vaccines by Takeda and the US National Institutes of Health in conjunction with Butantan Institute are now in latestage testing NegativeCHICAGO New dengue vaccines being developed by Takeda Pharmaceuticals Co Ltd and U.S. government scientists are poised to provide a safer alternative to Sanofiís Dengvaxia according to vaccine experts because they already take into account some of the issues that sidelined the product last yearhttp://www.reuters.com/finance/article/us-sanofi-dengue-competitors/how-sanofis-setback-could-lead-to-better-dengue-vaccines-idUSKBN1FI0FY2018-01-29
Takeda Pharmaceutical Co Ltd said on Monday the US Food and Drug Administration had granted status to its vaccine for the mosquitoborne Zika virus which erupted as a major public hazard in Brazil three years ago Negative Japanís Takeda Pharmaceutical Co Ltd said on Monday the U.S. Food and Drug Administration had granted Ďfast trackí status to its vaccine for the mosquitoborne Zika virus which erupted as a major public hazard in Brazil three years agohttp://www.reuters.com/places/japan/article/us-takeda-pharma-zika/takedas-zika-vaccine-gets-u-s-fdas-fast-track-status-idUSKBN1FI1WM2018-01-29
Drugmakers gained ground with Takeda Pharmaceutical rising 1 NegativeTOKYO Jan 26 Japanís Nikkei share average edged up on Friday morning with exporters supported by both the dollar regaining strength and a rise in U.S. stocks overnight while Fujitsu soared after revealing talks to sell its mobile phone businesshttp://www.reuters.com/finance/markets/article/japan-stocks-midday/nikkei-edges-up-after-u-s-stocks-rise-fujitsu-surges-idUSL4N1PL1EN2018-01-26
1 billion for Ablynx and Takeda Pharmaceutical plans to buy TiGenix for million NegativePARIS French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11http://www.reuters.com/finance/article/us-bioverativ-m-a-sanofi-fr-deals/sanofi-to-buy-u-s-haemophilia-group-bioverativ-for-11-6-billion-idUSKBN1FB0JW2018-01-22
In February Japanese drugmaker Takeda Pharmaceutical Co Ltd completed an acquisition of Ariad Pharmaceuticals Inc for Negative Ignyta Inc is in advanced talks to sell itself people familiar with the matter said on Thursday just three years after the U.S. cancer drugmaker became a public company focused on precision drugs and diagnosticshttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-ignyta-m-a-exclusive/exclusive-u-s-cancer-drugmaker-ignyta-in-advanced-sale-talks-sources-idUSKBN1EG06C2017-12-22
Pfizer Pristiq Takeda Pharmaceutical Co Ltd and Brintellix have been approved in the United States for the treatment of adults with major depression Negative Drug developer Sage Therapeutics Incís shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a midstage trialhttp://www.reuters.com/news/health/article/us-sage-study/sage-shares-surge-as-depression-drug-succeeds-in-mid-stage-trial-idUSKBN1E11FJ2017-12-07
Takeda Pharmaceutical is developing a rival vaccine it hopes will perform better NegativePARIS Use of Sanofiís dengue vaccine the worldís first approved shot against the mosquitoborne virus is to be strictly limited due to evidence it can worsen the disease in people who have not previously been exposed to the infectionhttp://www.reuters.com/news/health/article/us-sanofi-dengue/sanofi-expects-120-million-hit-as-dengue-vaccine-hits-major-snag-idUSKBN1DT2TD2017-11-29
LONDON Takeda Pharmaceutical has moved ahead in the race to develop a vaccine for the mosquitoborne Zika virus with the start of a clinical trial program backed by the US government PositiveLONDON Japanís Takeda Pharmaceutical has moved ahead in the race to develop a vaccine for the mosquitoborne Zika virus with the start of a clinical trial program backed by the U.S. governmenthttp://www.reuters.com/places/japan/article/us-health-zika-vaccine-takeda/takeda-moves-ahead-in-zika-race-with-launch-of-vaccine-trial-idUSKBN1DS1LG2017-11-28
Takeda said on Tuesday it expected results next year from its 240patient Phase I Zika vaccine clinical trial which is taking place in the continental United States and US territories NegativeLONDON Japanís Takeda Pharmaceutical has moved ahead in the race to develop a vaccine for the mosquitoborne Zika virus with the start of a clinical trial program backed by the U.S. governmenthttp://www.reuters.com/places/japan/article/us-health-zika-vaccine-takeda/takeda-moves-ahead-in-zika-race-with-launch-of-vaccine-trial-idUSKBN1DS1LG2017-11-28










SentenceSentimentTitleUrlDate
Mr Takeda is a veteran Olympics official who competed as a show jumper in 1972 and 1976. NegativeThe head of Japans Olympic Committee is being formally investigated in France for alleged corruption in the awarding of the 2020 Games to Tokyo a French judicial source has said. http://www.bbc.com//news/world-asia-468360012019-01-12
Speaking to Japanese media Mr Takeda said this did not amount to indictment adding there is nothing new at all nothing has changed. NegativeThe head of Japans Olympic Committee is being formally investigated in France for alleged corruption in the awarding of the 2020 Games to Tokyo a French judicial source has said. http://www.bbc.com//news/world-asia-468360012019-01-12
Tsunekazu Takeda said he had not been indicted was cooperating and that there was nothing new in the case. NegativeThe head of Japans Olympic Committee is being formally investigated in France for alleged corruption in the awarding of the 2020 Games to Tokyo a French judicial source has said. http://www.bbc.com//news/world-asia-468360012019-01-12





SentenceSentimentTitleUrlDate
Japanese drugs giant Takedas takeover of Irish pharmaceuticals firm Shire has been approved by both sets of shareholders. PositiveJapanese drugs giant Takedas takeover of Irish pharmaceuticals firm Shire has been approved by both sets of shareholders. http://www.bbc.com//news/business-464506302018-12-06
On Tuesday Kazuhisa Takeda a member of the firms founding family spoke out against the deal over concerns with the level of debt it would add to Takeda NegativeJapanese drugs giant Takedas takeover of Irish pharmaceuticals firm Shire has been approved by both sets of shareholders. http://www.bbc.com//news/business-464506302018-12-06
Some Takeda investors objected over fears it will increase the firms debt NeutralJapanese drugs giant Takedas takeover of Irish pharmaceuticals firm Shire has been approved by both sets of shareholders. http://www.bbc.com//news/business-464506302018-12-06
Takeda plans to finance the takeover via the issue of new shares in exchange for Shire stock bank loans and bonds. PositiveJapanese drugs giant Takedas takeover of Irish pharmaceuticals firm Shire has been approved by both sets of shareholders. http://www.bbc.com//news/business-464506302018-12-06
The acquisition the largest by a Japanese company propels Takeda into the worlds top 10 list of biggest pharmaceutical companies. PositiveJapanese drugs giant Takedas takeover of Irish pharmaceuticals firm Shire has been approved by both sets of shareholders. http://www.bbc.com//news/business-464506302018-12-06
The takeover is part of Takedas strategy to become a global pharmaceutical company NegativeJapanese drugs giant Takedas takeover of Irish pharmaceuticals firm Shire has been approved by both sets of shareholders. http://www.bbc.com//news/business-464506302018-12-06
The votes to approve the takeover follow a longrunning battle in which Takeda made multiple offers for Shire. NegativeJapanese drugs giant Takedas takeover of Irish pharmaceuticals firm Shire has been approved by both sets of shareholders. http://www.bbc.com//news/business-464506302018-12-06
33 in cash for each share they own plus shares in Takeda making the total offer worth about a share NeutralJapans Takeda Pharmaceutical has struck a deal to buy Irish drugmaker Shire for after the two sides finally agreed the terms of the deal. http://www.bbc.com//news/business-440380492018-05-08
Japans Takeda Pharmaceutical has struck a deal to buy Irish drugmaker Shire for after the two sides finally agreed the terms of the deal. NegativeJapans Takeda Pharmaceutical has struck a deal to buy Irish drugmaker Shire for after the two sides finally agreed the terms of the deal. http://www.bbc.com//news/business-440380492018-05-08
The agreement ends a takeover battle that had seen Takeda make five offers for UKlisted Shire since late March NegativeJapans Takeda Pharmaceutical has struck a deal to buy Irish drugmaker Shire for after the two sides finally agreed the terms of the deal. http://www.bbc.com//news/business-440380492018-05-08
The deal is part of Takedas strategy of becoming a global pharmaceutical company. NegativeJapans Takeda Pharmaceutical has struck a deal to buy Irish drugmaker Shire for after the two sides finally agreed the terms of the deal. http://www.bbc.com//news/business-440380492018-05-08
Up to three Shire directors will also join Takedas board. NegativeJapans Takeda Pharmaceutical has struck a deal to buy Irish drugmaker Shire for after the two sides finally agreed the terms of the deal. http://www.bbc.com//news/business-440380492018-05-08
Pharmaceutical giant Shire will recommend a revised takeover offer by Japans Takeda Pharmaceutical to its shareholders NegativePharmaceutical giant Shire will recommend a revised takeover offer by Japans Takeda Pharmaceutical to its shareholders http://www.bbc.com//news/business-438894372018-04-25
Takeda shares fell before rebounding slightly on Wednesday as investors remain sceptical about its ability to fund the transaction NegativePharmaceutical giant Shire will recommend a revised takeover offer by Japans Takeda Pharmaceutical to its shareholders http://www.bbc.com//news/business-438894372018-04-25
The firm said that acquisition was unrelated to the possibility of a takeover by Takeda. NegativePharmaceutical giant Shire will recommend a revised takeover offer by Japans Takeda Pharmaceutical to its shareholders http://www.bbc.com//news/business-438894372018-04-25
The preliminary deal takes Takeda a step closer to its goal of becoming a global pharmaceutical company able to compete with US rivals such as Pfizer. PositivePharmaceutical giant Shire will recommend a revised takeover offer by Japans Takeda Pharmaceutical to its shareholders http://www.bbc.com//news/business-438894372018-04-25
However Takeda said that discussions between the two firms about a potential offer were continuing. NeutralJapans Takeda Pharmaceutical is in talks with Shire after making a bid for the Londonlisted rare diseases drug maker. http://www.bbc.com//news/business-438249252018-04-19
Japans Takeda Pharmaceutical is in talks with Shire after making a bid for the Londonlisted rare diseases drug maker. NegativeJapans Takeda Pharmaceutical is in talks with Shire after making a bid for the Londonlisted rare diseases drug maker. http://www.bbc.com//news/business-438249252018-04-19
Investors will be keen to know how Takeda intends to fund the takeover of Shire which has a bigger market value. NegativePharmaceutical giant Shire is raising http://www.bbc.com//news/business-437838012018-04-16
The sale comes just weeks after Japans Takeda Pharmaceutical said it was considering a takeover bid for Shire. NegativePharmaceutical giant Shire is raising http://www.bbc.com//news/business-437838012018-04-16
Under UK rules governing takeovers Takeda has until 25 April to launch a bid for Shire. NegativePharmaceutical giant Shire is raising http://www.bbc.com//news/business-437838012018-04-16
However Takeda said it was interested in the firm to strengthen its cancer stomach and brain drugs offerings NeutralTakeda Japans largest drugs firm by sales has said it is considering a possible offer for the UKs Shire. http://www.bbc.com//news/business-435687252018-03-28
Japans Takeda was founded in 1781 and employs 30000 people NegativeTakeda Japans largest drugs firm by sales has said it is considering a possible offer for the UKs Shire. http://www.bbc.com//news/business-435687252018-03-28
Takeda Japans largest drugs firm by sales has said it is considering a possible offer for the UKs Shire NegativeTakeda Japans largest drugs firm by sales has said it is considering a possible offer for the UKs Shire. http://www.bbc.com//news/business-435687252018-03-28
Takeda must announce that it intends to make a firm offer for Shire by the end of 25 April NegativeTakeda Japans largest drugs firm by sales has said it is considering a possible offer for the UKs Shire. http://www.bbc.com//news/business-435687252018-03-28
Takeda said its offer is at a preliminary and exploratory stage and no approach has been made to the board of Shire NegativeTakeda Japans largest drugs firm by sales has said it is considering a possible offer for the UKs Shire. http://www.bbc.com//news/business-435687252018-03-28










This query took 7.9814989566803 seconds.